Vaccination Strategies against Malaria: novel carrier(s) more than a tour de force

Tyagi, Rajeev K.; Garg, Neeraj; Sahu, Tejram

doi:10.1016/j.jconrel.2012.04.037

Cited by 30 publications

(23 citation statements)

References 154 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, liposome loaded with cytostatic drugs for cancer therapeutics is reported to cause more or less immune suppression [48]. These drug-loaded formulations opened new avenues in cancer immunotherapeutics.…”

Section: Immunosuppression By Liposome-mediated Delivery Of Specific mentioning

confidence: 99%

“…The immunosuppression was seen from the long-lived persistence of bacteria in the blood stream. We have tried immunomodulatory and pharmacological reagents/chemicals which were used to further suppress the residual innate immune response ( Table 1) [47][48][49][50] of huRBC reconstituted immunodeficient mouse (huRBC-NSG) for the engraftment and survival of P. falciparum. Also, immunosuppression of nonadaptive residual immune responses of immunodeficient mouse was contained by clodronate-loaded liposomes in order to achieving significant huRBC grating in immunodeficient animals (NSG) (Figure 2).…”

Section: Immunosuppression By Liposome-mediated Delivery Of Specific mentioning

confidence: 99%

“…which is highly evolved and a complex organism. The mercurial behavior of parasite because of the secretion of tens of thousands of proteins [4,5,48]. A) Upper panel shows significant human blood chimerism in NSG mice over the period of more than 21 days, and B) lower panel illustrates the sizeable parasitemia using three (PAM, 3D7 and K1) P. falciparum strains in the huRBC reconstituted NSG mice.…”

Section: The Malaria Vaccine Development: a Challenging Taskmentioning

confidence: 99%

“…Liposomes are tools that can be used in tumor-targeting, gene-silencing, antisense therapy; immunomodulation; and genetic vaccination [48]. Liposomes (pH-sensitive liposomes) are majorly used for targeted and cytosolic delivery of vaccine candidate for achieving perdurable immune responses as well as delivery of drugs.…”

Section: Liposome As a Vaccine Candidatementioning

confidence: 99%

See 3 more Smart Citations

Liposome-Mediated Immunosuppression Plays an Instrumental Role in the Development of “Humanized Mouse” to Study Plasmodium falciparum

Agrawal¹,

Vyas²,

Hafeji³

et al. 2017

Liposomes

Self Cite

View full text Add to dashboard Cite

The material world has been getting prone toward infectious diseases, and therefore novel strategies should be devised to treat chronic infectious disorders. The translational biomedical research scientists made early attempts to develop mouse-human chimera (humanized mouse) through the reconstitution of immunodeficient mouse with engraftment of human cells and tissues. Although the humanized mouse proved to be an effective tool in understanding various diseases such as human malaria and hepatitis, however, drug administration, retention capacity of the administered drug, toxicity, and ethical constraints are some of the major issues and need to be objectively addressed. The "humanization" of immunodeficient mouse needs pharmacological immunomodulatory reagents to control the excessively recruited cells of monocytemacrophage lineage. Therefore, administration of liposome loaded with hydrophobic drug (clodronate) to induce selective apoptosis through "suicidal approach" in myeloid cells plays an instrumental role for controlling residual nonadaptive immune response of the host. Liposomes are spherical and hollow-structures consisting of lipid bilayer-and are used for the delivery of drug and vaccine candidates. The surfaceengineered liposomes (ligand anchored) are used for targeted and controlled delivery. Clodronate-loaded liposomes play a pivotal role in developing humanized mouse. This mouse holds relevance to study pathophysiology and immunopathology of human malaria parasite, P. falciparum. The liposomal delivery of clodronate administered in immunodeficient mice to modulate their innate immune system is an amenable strategy with the minimal/acceptable range of systemic toxicity.

show abstract

Section: Immunosuppression By Liposome-mediated Delivery Of Specific mentioning

confidence: 99%

Section: Immunosuppression By Liposome-mediated Delivery Of Specific mentioning

confidence: 99%

Section: The Malaria Vaccine Development: a Challenging Taskmentioning

confidence: 99%

Section: Liposome As a Vaccine Candidatementioning

confidence: 99%

See 2 more Smart Citations

Liposome-Mediated Immunosuppression Plays an Instrumental Role in the Development of “Humanized Mouse” to Study Plasmodium falciparum

Agrawal¹,

Vyas²,

Hafeji³

et al. 2017

Liposomes

Self Cite

View full text Add to dashboard Cite

show abstract

“…18,19 Long-term persistence of the presented immunogen is also achieved via DNA vaccination. Other benefits of a DNA-based vaccine include its ability to polarize T-cell help, especially to a Th1 immunological response, as well as ease in the burden of production, compared with a protein-based vaccine.…”

Section: Introductionmentioning

confidence: 99%

Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles

Cambridge¹,

Singh²,

Waffo³

et al. 2013

IJN

View full text Add to dashboard Cite

Chlamydia trachomatis is a bacterial sexually transmitted infection affecting millions of people worldwide. Previous vaccination attempts have employed the recombinant major outer membrane protein (MOMP) of C. trachomatis nonetheless, with limited success, perhaps, due to stability, degradation, and delivery issues. In this study we cloned C. trachomatis recombinant MOMP DNA (DMOMP) and encapsulated it in chitosan nanoparticles (DMCNP) using the complex coacervation technique. Physiochemical characterizations of DMCNP included transmission and scanning electron microcopy, Fourier transform infrared and ultravioletvisible spectroscopy, and zeta potential. Encapsulated DMOMP was 167-250 nm, with a uniform spherical shape and homogenous morphology, and an encapsulation efficiency . 90%. A slow release pattern of encapsulated DMOMP, especially in acidic solution, was observed over 7 days. The zeta potential of DMCNP was ∼8.80 mV, which indicated that it was highly stable. Toxicity studies of DMCNP (25-400 µg/mL) to Cos-7 cells using the MTT assay revealed minimal toxicity over 24-72 hours with .90% viable cells. Ultra-violet visible (UV-vis) spectra indicated encapsulated DMOMP protection by chitosan, whereas agarose gel electrophoresis verified its protection from enzymatic degradation. Expression of MOMP protein in DMCNPtransfected Cos-7 cells was demonstrated via Western blotting and immunofluorescence microscopy. Significantly, intramuscular injection of BALB/c mice with DMCNP confirmed the delivery of encapsulated DMOMP, and expression of the MOMP gene transcript in thigh muscles and spleens. Our data show that encapsulation of DMOMP in biodegradable chitosan nanoparticles imparts stability and protection from enzymatic digestion, and enhances delivery and expression of DMOMP in vitro and in mice. Further investigations of the nanoencapsulated DMCNP vaccine formulation against C. trachomatis in mice are warranted.

show abstract

Therapeutic Applications of Nanotechnology in the Prevention of Infectious Diseases

Mazumdar

Thakur

2022

Nanotechnology in the Life Sciences

View full text Add to dashboard Cite

Vaccination Strategies against Malaria: novel carrier(s) more than a tour de force

Cited by 30 publications

References 154 publications

Liposome-Mediated Immunosuppression Plays an Instrumental Role in the Development of “Humanized Mouse” to Study Plasmodium falciparum

Liposome-Mediated Immunosuppression Plays an Instrumental Role in the Development of “Humanized Mouse” to Study Plasmodium falciparum

Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles

Therapeutic Applications of Nanotechnology in the Prevention of Infectious Diseases

Contact Info

Product

Resources

About